



National Institutes of Health/ NCI
9609 Medical Center Drive, Suite 530
Rockville, MD 20852
Office (240) 276-5530
Facsimile (240) 276-5504

VIA E-MAIL ONLY

James Love and Claire Cassedy
Knowledge Ecology International
1621 Connecticut Ave. NW, Suite 500
Washington, DC 20009

IN RE: Prospective Grant of an Exclusive Patent License: Use of A CD47 Phosphorodiamidate Morpholino Oligomer for the Treatment, Prevention, and Diagnosis Of Cancer, published on 28 December 2020 in *Federal Register* Vol. 85, No. 248, pages 84359-84361

Dear James Love and Claire Cassedy:

Thank you for providing us with your comments regarding the notice of intent to grant a license to Morphix Biotherapeutics (“Morphix”) by the National Cancer Institute (NCI).

Prior to posting a notice for a proposed grant of an exclusive license, the NCI determines that the criteria set forth in 37 CFR 404.7(a)(1)(ii-iii) have been satisfied and that the company is qualified both technically and financially to be granted an exclusive license to the Government’s intellectual property in the fields of use as specified. The notice period provides an opportunity for public comment and possible objection to the proposed license. We consider all comments prior to negotiating the proposed license.

Your suggestions of license terms will be given full consideration as we move forward with negotiating an exclusive license to Morphix for NCI technologies E-227-2006-0,-1, -2, -3, -4,-5; E-086-2012-0, -1, -2; E-153-2008-0; E-296-2011-0; and E-263-2014-0 in the limited field of use described in the notice.

NCI has determined that your comments did not raise an issue that would preclude the grant of the proposed exclusive license, and the NCI intends to proceed with the negotiation of the license.

Sincerely,

Jaime M. Greene, M.S.
Senior Technology Transfer Manager
National Cancer Institute, TTC
greenejaime@mail.nih.gov